Key Drivers
- Strong Cash Runway
- Ongoing Cash Burn
- Significant Dilution
AIAI Summary
Immix is now funded into mid-2028, shifting the thesis from near-term financing risk to a high-stakes bet on September's full NXC-201 data and a credible 2027 BLA path; investors should wait for validation or size positions cautiously given the already elevated valuation, dilution, and serious governance overhang.
Price Chart
Financial Metrics
Deep Analysis
Research tool. Not personalized advice.
Fundamental Analysis
Key Financial Insights:
- •Strong Cash Runway
- •Ongoing Cash Burn
- •Significant Dilution
IMMX's strong cash position and low debt provide runway, but persistent losses, no revenue, high cash burn, and equity-driven dilution make it a high-risk investment.
Price Behavior
Key Price Behavior Insights:
- •Strong upward trend
- •Overbought momentum
- •Resistance test
IMMX remains bullish after a 68% last-month surge, but overbought momentum near $14.47 resistance raises pullback risk toward $13.60–$13.20.
Sharp 68% rise from $8.32 to $13.94 over the last month signals elevated volatility
Sentiment & News
Key News Insights:
- •12-Month High
- •Investor Outreach
- •Legal Scrutiny
Immix Biopharma hit a 12-month high amid investor outreach plans, though ongoing legal investigations pose a material risk.
Strong momentum may support near-term interest, but legal developments could heighten volatility
Similar Companies in Healthcare
Other companies in the same sector with AI ratings